Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Taking oral or subcutaneous methotrexate
Patients who have given written informed consent
Patients with psoriasis
...
Taking oral or subcutaneous methotrexate
Patients who have given written informed consent
Patients with psoriasis
Measurement of methotrexate polyglutamates on at least one occasion during therapy.

Exclusion Criteria

Unable to consent
Not taking methotrexate
Unable to consent
Not taking methotrexate

Summary

Conditions
  • Injury of Liver
  • Psoriasis Chronic
Type
Observational
Design
Observational Model: Cohort

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Data for this study is drawn from the BSTOP (Biomarkers of Systemic Treatment Outcomes in Psoriasis) cohort. This is a multi-centre, prospective, cohort study to establish clinically relevant biomarkers and pharmacogenetic markers of systemic treatment outcomes in patients with severe psoriasis.

Data for this study is drawn from the BSTOP (Biomarkers of Systemic Treatment Outcomes in Psoriasis) cohort. This is a multi-centre, prospective, cohort study to establish clinically relevant biomarkers and pharmacogenetic markers of systemic treatment outcomes in patients with severe psoriasis.

Inclusion Criteria

Taking oral or subcutaneous methotrexate
Patients who have given written informed consent
Patients with psoriasis
...
Taking oral or subcutaneous methotrexate
Patients who have given written informed consent
Patients with psoriasis
Measurement of methotrexate polyglutamates on at least one occasion during therapy.

Exclusion Criteria

Unable to consent
Not taking methotrexate
Unable to consent
Not taking methotrexate

Tracking Information

NCT #
NCT02174354
Collaborators
Not Provided
Investigators
  • Principal Investigator: Catherine H Smith, MD Kings College London and Guys and St Thomas' NHS Foundation Trust
  • Catherine H Smith, MD Kings College London and Guys and St Thomas' NHS Foundation Trust